Lexicon Pharmaceuticals Inc
F:LX31
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
L
|
Lexicon Pharmaceuticals Inc
F:LX31
|
US |
|
PPC Ltd
F:OZV2
|
ZA |
|
Helius Medical Technologies Inc
NASDAQ:HSDT
|
US |
|
Indus Towers Ltd
NSE:INDUSTOWER
|
IN |
|
B
|
Boombit SA
WSE:BBT
|
PL |
|
Arca Continental SAB de CV
OTC:EMBVF
|
MX |
|
H
|
Haseko Corp
XBER:HS6
|
JP |
|
Circle Internet Group Inc
F:ET9
|
US |
|
W
|
Workiva Inc
F:0WKA
|
US |
|
A
|
American States Water Co
SWB:FDK
|
US |
|
Dianomi PLC
F:3NJ
|
UK |
|
C
|
Coffee Holding Co Inc
F:E6U
|
US |
|
C
|
Ctac NV
XBER:TAC
|
NL |
|
N
|
NK Lukoil PAO
F:LUK
|
RU |
|
U
|
USANA Health Sciences Inc
F:USJ
|
US |
Wall St Price Targets
LX31 Price Targets Summary
Lexicon Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for LX31 is 4.839 EUR with a low forecast of 2.224 EUR and a high forecast of 7.927 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is LX31's stock price target?
Price Target
4.839
EUR
According to Wall Street analysts, the average 1-year price target for LX31 is 4.839 EUR with a low forecast of 2.224 EUR and a high forecast of 7.927 EUR.
What is the Revenue forecast for Lexicon Pharmaceuticals Inc?
Projected CAGR
41%
Over the last 13 years, the compound annual growth rate for Revenue has been 34%. The projected CAGR for the next 8 years is 41%.
What is the Gross Profit forecast for Lexicon Pharmaceuticals Inc?
Projected CAGR
41%
The compound annual growth rate for Gross Profit over the next 8 years is 41%.
